Handok and Novartis Korea signed a domestic sales contract for four respiratory products on December 19, 2022.

Handok was responsible for domestic sales of Onbrez in 2013, and with this contract, it will supervise the sale of three additional products: Xoturna, Enerzair, and Atectura. From January 1, 2023, Handok will exclusively handle domestic distribution, sales, and promotion of these products.

Onbrez and Xoturna are treatments for chronic obstructive pulmonary disease (COPD). Onbrez (active ingredient: indacaterol) is an inhaled bronchodilator used for maintenance therapy of chronic obstructive pulmonary disease. Xoturna (active ingredient: indacaterol/glycopyrronium) is a combined treatment for chronic obstructive pulmonary disease consisting of two bronchodilators, long-acting beta 2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium.

Enerzair and Atectura are treatments for asthma. “Enerzair (active ingredients: mometasone, indacaterol, glycopyrronium) is the first ICS (inhaled corticosteroid)/LABA/LAMA combination for asthma treatment. Atectura (active ingredients: mometasone and indacaterol) is a once-daily combination treatment for asthma.